Omicron variant evolution on vaccines and monoclonal antibodies.
Antiviral drugs
B.1.1.529
COVID-19
Coronavirus
Epidemiology
Monoclonal antibodies
Mutations
Omicron
Pandemic
Public health
SARS-CoV-2
Spike protein
VOC
VOI
Vaccines
Variants
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
28
04
2023
accepted:
09
05
2023
medline:
19
7
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
The severe acute respiratory syndrome coronavirus (SARS-CoV)-2 responsible for the global COVID-19 pandemic has caused almost 760 million confirmed cases and 7 million deaths worldwide, as of end-February 2023. Since the beginning of the first COVID-19 case, several virus variants have emerged: Alpha (B1.1.7), Beta (B135.1), Gamma (P.1), Delta (B.1.617.2) and then Omicron (B.1.1.529) and its sublineages. All variants have diversified in transmissibility, virulence, and pathogenicity. All the newly emerging SARS-CoV-2 variants appear to contain some similar mutations associated with greater "evasiveness" of the virus to immune defences. From early 2022 onward, several Omicron subvariants named BA.1, BA.2, BA.3, BA.4, and BA.5, with comparable mutation forms, have followed. After the wave of contagions caused by Omicron BA.5, a new Indian variant named Centaurus BA.2.75 and its new subvariant BA.2.75.2, a second-generation evolution of the Omicron variant BA.2, have recently been identified. From early evidence, it appears that this new variant has higher affinity for the cell entry receptor ACE-2, making it potentially able to spread very fast. According to the latest studies, the BA.2.75.2 variant may be able to evade more antibodies in the bloodstream generated by vaccination or previous infection, and it may be more resistant to antiviral and monoclonal antibody drug treatments. In this manuscript, the authors highlight and describe the latest evidences and critical issues have emerged on the new SARS-CoV-2 variants.
Identifiants
pubmed: 37204696
doi: 10.1007/s10787-023-01253-6
pii: 10.1007/s10787-023-01253-6
pmc: PMC10198014
doi:
Substances chimiques
Antibodies, Monoclonal
0
Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1779-1788Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Balse E, Hatem SN (2021) Do cellular entry mechanisms of SARS-Cov-2 affect myocardial cells and contribute to cardiac injury in COVID-19 patients? Front Physiol 12:630778. https://doi.org/10.3389/fphys.2021.630778
doi: 10.3389/fphys.2021.630778
pubmed: 33767634
pmcid: 7985088
Callaway E (2022a) New Omicron relatives BA.4 and BA.5 offer hints about the future of SARS-CoV-2. Nature 605:204–206
doi: 10.1038/d41586-022-01240-x
pubmed: 35523871
Callaway E (2022b) What Omicron’s BA.4 and BA.5 variants mean for the pandemic. Nature 606(7916):848–849. https://doi.org/10.1038/d41586-022-01730-y
doi: 10.1038/d41586-022-01730-y
pubmed: 35750920
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS (2022) BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608(7923):593–602. https://doi.org/10.1038/s41586-022-04980-y . (Epub 2022 Jun 17)
doi: 10.1038/s41586-022-04980-y
pubmed: 35714668
pmcid: 9385493
Cele S, Jackson L, Khoury DS et al (2022) Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602:654–656
doi: 10.1038/s41586-021-04387-1
pubmed: 35016196
Cohen C, Kleynhans J, von Gottberg A et al (2022) SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21. Lancet Infect Dis 22(6):821–834. https://doi.org/10.1016/S1473-3099(22)00069-X
doi: 10.1016/S1473-3099(22)00069-X
pubmed: 35298900
pmcid: 8920516
Conti P, Pregliasco FE, Calvisi V, Al C, Gallenga CE, Kritas SK, Ronconi G (2021) Monoclonal antibody therapy in COVID-19. J Biol Regul Homeost Agents 35(2):423–427. https://doi.org/10.23812/Conti_Edit_35_2_1
doi: 10.23812/Conti_Edit_35_2_1
pubmed: 33904269
Coronavirus (COVID-19) Infection Survey, UK: 4 November 2022—Office for National Statistics. https://www.ons.gov.uk/releases/coronaviruscovid19infectionsurveyuk4november2022 . Accessed 21 Nov 2022
da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, Monteiro Arnozo G, Rodrigues da Silva Filho E, Galdino Dos Santos AG, Oliveira da Cunha EJ, Salgueiro de Aquino SH, Freire de Souza CD (2021) Clinical manifestations of COVID-19 in the general population: systematic review. Wien Klin Wochenschr. 133(7–8):377–382. https://doi.org/10.1007/s00508-020-01760-4 . (Epub 2020 Nov 26)
doi: 10.1007/s00508-020-01760-4
pubmed: 33242148
European Centre for Disease Prevention and Control (2023a) Country overview report: week 8 2023a. Produced on 1 March 2023a at 18.00. https://covid19-country-overviews.ecdc.europa.eu/variants_of_concern.html
European Centre for Disease Prevention and Control (2023b) Epidemiological update: SARS‐CoV‐2 Omicron sub‐lineages BA.4 and BA.5.2022
Ferrara F, Porta R, Daiuto V, Vitiello A (2021) Remdesivir and COVID-19. Ir J Med Sci 190(3):1237–1238. https://doi.org/10.1007/s11845-020-02401-5 . (Epub 2020 Oct 17)
doi: 10.1007/s11845-020-02401-5
pubmed: 33068241
Gurung AB, Ali MA, Aljowaie RM, Almutairi SM, Sami H, Lee J (2023) Masitinib analogues with the N-methylpiperazine group replaced—a new hope for the development of anti-COVID-19 drugs. J King Saud Univ Sci 35(1):102397. https://doi.org/10.1016/j.jksus.2022.102397 . (Epub 2022 Oct 31)
doi: 10.1016/j.jksus.2022.102397
pubmed: 36406239
Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J, Rowe M, Bondzie EA, Powers O, Surve N, Hall K, Barouch DH (2022) Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 387(1):86–88. https://doi.org/10.1056/NEJMc2206576 . (Epub 2022 Jun 22)
doi: 10.1056/NEJMc2206576
pubmed: 35731894
Halfmann PJ et al (2022) SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. https://doi.org/10.1038/s41586-022-04441-6 . [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Han Q, Zheng B, Daines L, Sheikh A (2022) Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens 11(2):269. https://doi.org/10.3390/pathogens11020269
doi: 10.3390/pathogens11020269
pubmed: 35215212
pmcid: 8875269
Hirotsu Y, Omata M (2023) Detection of the omicron BA.2.75 subvariant in Japan. J Infect 86(1):e5–e7. https://doi.org/10.1016/j.jinf.2022.08.038
doi: 10.1016/j.jinf.2022.08.038
pubmed: 36087746
Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280
doi: 10.1016/j.cell.2020.02.052
pubmed: 32142651
pmcid: 7102627
https://www.ecdc.europa.eu/en/covid-19/country-overviews
https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-latest-updates
https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Islam MR, Shahriar M, Bhuiyan MA (2022) The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: a threat to global public health. Health Sci Rep 5(6):e884. https://doi.org/10.1002/hsr2.884
doi: 10.1002/hsr2.884
pubmed: 36254237
pmcid: 9561426
Jorgensen SCJ, Tse CLY, Burry L, Dresser LD (2020) Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy 40(8):843–856. https://doi.org/10.1002/phar.2438 . (Epub 2020 Jul 27)
doi: 10.1002/phar.2438
pubmed: 32542785
pmcid: 7323235
Kawaoka Y, Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann P, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Matsubara S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Okuda M, Murakami J, Duong C, Godbole S, Douek D, Watanabe S, Ohmagari N, Yotsuyanagi H, Diamond M, Hasegawa H, Mitsuya H, Suzuki T (2022) Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Res Sq [Preprint]. https://doi.org/10.21203/rs.3.rs-1375091/v1 . Update in: Nature. 2022 May 16
Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY (2022) Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med 28(9):1933–1943. https://doi.org/10.1038/s41591-022-01887-z . (Epub 2022 Jun 8)
doi: 10.1038/s41591-022-01887-z
pubmed: 35675841
pmcid: 10208005
Liu L, Iketani S, Guo Y et al (2022) Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature 602:676–681
doi: 10.1038/s41586-021-04388-0
pubmed: 35016198
Lyngse F et al (2022) Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish households. medRxiv. https://doi.org/10.1101/2022.01.28.22270044 . [CrossRef] [Google Scholar]
Mantzourani C, Vasilakaki S, Gerogianni VE, Kokotos G (2022) The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19. Expert Opin Drug Discov 17(3):231–246. https://doi.org/10.1080/17460441.2022.2029843 . (Epub 2022 Jan 24)
doi: 10.1080/17460441.2022.2029843
pubmed: 35072549
Mouffak S, Shubbar Q, Saleh E, El-Awady R (2021) Recent advances in management of COVID-19: a review. Biomed Pharmacother. 143:112107. https://doi.org/10.1016/j.biopha.2021.112107 . (Epub 2021 Aug 27)
doi: 10.1016/j.biopha.2021.112107
pubmed: 34488083
pmcid: 8390390
Parikh S, O’Laughlin K, Ehrlich HY et al (2020) Point prevalence testing of residents for SARS-CoV-2 in a subset of Connecticut nursing homes. JAMA 324(11):1101–1103. https://doi.org/10.1001/jama.2020.14984
doi: 10.1001/jama.2020.14984
pubmed: 32790860
pmcid: 7418038
Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U (2020) The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol 49(3):717–726. https://doi.org/10.1093/ije/dyaa033
doi: 10.1093/ije/dyaa033
pubmed: 32086938
Petrovszki D, Walter FR, Vigh JP, Kocsis A, Valkai S, Deli MA, Dér A (2022) Penetration of the SARS-CoV-2 spike protein across the blood–brain barrier, as revealed by a combination of a human cell culture model system and optical biosensing. Biomedicines 10(1):188. https://doi.org/10.3390/biomedicines10010188
doi: 10.3390/biomedicines10010188
pubmed: 35052867
pmcid: 8773803
Real-time dashboard. Coronavirus disease 2019. https://covid19.sph.hku.hk/dashboard . Accessed 5 Mar 2023
Shaheen N, Mohamed A, Soliman Y, Abdelwahab OA, Diab RA, Desouki MT, Rababah AA, Khaity A, Hefnawy MT, Swed S, Shaheen A, Elfakharany B, Shoib S (2022) Could the new BA.2.75 sub-variant lead to another COVID-19 wave in the world?—Correspondence. Int J Surg 105:106861. https://doi.org/10.1016/j.ijsu.2022.106861 . (Epub 2022 Aug 27)
doi: 10.1016/j.ijsu.2022.106861
pubmed: 36031071
pmcid: 9420005
Sheward DJ, Kim C, Fischbach J, Muschiol S, Ehling RA, Björkström NK et al (2022a) Evasion of neutralising antibodies by omicron sublineage BA.2.75. Lancet Infect Dis 22(10):1421–1422. https://doi.org/10.1016/S1473-3099(22)00524-2
doi: 10.1016/S1473-3099(22)00524-2
pubmed: 36058228
pmcid: 9436366
Sheward DJ, Kim C, Fischbach J, Muschiol S, Ehling RA, Björkström NK, KarlssonHedestam GB, Reddy ST, Albert J, Peacock TP, Murrell B (2022b) Evasion of neutralising antibodies by omicron sublineage BA.2.75. Lancet Infect Dis 22(10):1421–1422. https://doi.org/10.1016/S1473-3099(22)00524-2 . (Epub 2022 Sep 1)
doi: 10.1016/S1473-3099(22)00524-2
pubmed: 36058228
pmcid: 9436366
Sheward DJ, Kim C, Fischbach J, Sato K, Muschiol S, Ehling RA, Björkström NK, KarlssonHedestam GB, Reddy ST, Albert J, Peacock TP, Murrell B (2022c) Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. Lancet Infect Dis 22(11):1538–1540. https://doi.org/10.1016/S1473-3099(22)00663-6 . (Epub 2022 Oct 14)
doi: 10.1016/S1473-3099(22)00663-6
pubmed: 36244347
pmcid: 9560757
Shuai H et al (2022) Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. https://doi.org/10.1038/s41586-022-04442-5 . [PubMed] [CrossRef] [Google Scholar]
Suzuki R et al (2022) Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. https://doi.org/10.1038/s41586-022-04462-1 . [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y (2022) Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med 387(5):468–470. https://doi.org/10.1056/NEJMc2207519 . (Epub 2022 Jul 20)
doi: 10.1056/NEJMc2207519
pubmed: 35857646
Times TE (2022) Omicron's new 'BA.2.75.2' variant growing quickly in India, becoming more transmissible, immune evasive: Scientists. https://economictimes.indiatimes.com/news/pune-news/omicrons-new-ba-2-75-2-variant-growing-quickly-in-india-becoming-more-transmissible-immune-evasive-scientists/articleshow/94128543.cms
Tso WWY, Kwan MYW, Wang YL, Leung LK, Leung D, Chua GT, Ip P, Fong DYT, Wong WHS, Chan SHS, Chan JFW, Peiris M, Lau YL, Rosa Duque JS (2022) Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. Emerg Microbes Infect 11(1):1742–1750. https://doi.org/10.1080/22221751.2022.2093135
doi: 10.1080/22221751.2022.2093135
pubmed: 35730665
pmcid: 9258055
Vitiello A, Ferrara F (2021) Brief review of the mRNA vaccines COVID-19. Inflammopharmacology 29(3):645–649. https://doi.org/10.1007/s10787-021-00811-0 . (Epub 2021 May 1)
doi: 10.1007/s10787-021-00811-0
pubmed: 33932192
pmcid: 8087898
Vitiello A, Ferrara F, Troiano V, La Porta R (2021) COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology 29(5):1357–1360. https://doi.org/10.1007/s10787-021-00847-2 . (Epub 2021 Jul 19)
doi: 10.1007/s10787-021-00847-2
pubmed: 34279767
pmcid: 8287551
Vitiello A, Ferrara F, Auti AM, Di Domenico M, Boccellino M (2022) Advances in the Omicron variant development. J Intern Med 292(1):81–90. https://doi.org/10.1111/joim.13478 . (Epub 2022 Mar 22)
doi: 10.1111/joim.13478
pubmed: 35289434
pmcid: 9115048
WHO (2023a) XBB.1.5 updated risk assessment, 24 February 2023. https://www.who.int/docs/default-source/coronaviruse/22022024xbb.1.5ra.pdf
WHO (2023b) Coronavirus disease (COVID-19) Weekly epidemiological updates and monthly operational updates. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports . Accessed 5 Mar 2023
WHO (2023c) WHO updates COVID-19 guidelines on masks, treatments and patient care. https://www.who.int/news/item/13-01-2023-who-updates-covid-19-guidelines-on-masks--treatments-and-patient-care
Statement on the update of WHO’s working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest. Accessed 16 March 2023. https://www.who.int/news/item/16-03-2023d-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest
Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome MJ, Amoako DG, Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Subramoney K, Makatini Z, Hsiao NY, Parboosing R, Wadula J, Hussey H, Davies MA, Boulle A, von Gottberg A, Cohen C (2022) Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat Commun 13(1):5860. https://doi.org/10.1038/s41467-022-33614-0
doi: 10.1038/s41467-022-33614-0
pubmed: 36195617
pmcid: 9531215
Zappa M, Verdecchia P, Angeli F (2022) Knowing the new Omicron BA.2.75 variant (‘Centaurus’): a simulation study. Eur J Intern Med 105:107–108. https://doi.org/10.1016/j.ejim.2022.08.009
doi: 10.1016/j.ejim.2022.08.009
pubmed: 35981914
pmcid: 9376787
Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y (2020) From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res 21(1):224. https://doi.org/10.1186/s12931-020-01479-w
doi: 10.1186/s12931-020-01479-w
pubmed: 32854739
pmcid: 7450684